Functional impact of androgen‐targeted therapy on patients with castration‐resistant prostate cancer

ABSTRACT: Abstract

Context

Second‐generation androgen receptor inhibitors (ARIs) extend metastasis‐free survival, prolong overall survival, and delay symptoms when added to androgen deprivation therapy for the treatment of castration‐sensitive or castration‐resistant prostate cancer (CRPC). However, ARIs may adversely impact physical and cognitive function, thereby decreasing quality of life and prognosis.

Objective

To evaluate the evidence regarding the potential effects of ARIs on physical and cognitive function and to contextualize how drug‐related adverse effects may influence treatment decisions in CRPC.

Evidence acquisition

We performed a literature search using MEDLINE from January 1998 to June 2020 using terms relating to prostate cancer, androgen deprivation, and

SUBMITTER: Beer T 

PROVIDER: S-EPMC9579880 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature